FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

As South Africans continue to experience the winter chill, the National Institute for Communicable Diseases ( NICD is urging ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...

You’re not imagining it, flu cases are on the rise this season, as vaccination levels decline and COVID-style social ...

Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Newborns are at risk for serious complications from influenza infections but are not eligible for vaccination until they are ...